Orion Portfolio Solutions LLC Has $33.64 Million Position in Eli Lilly and Company (NYSE:LLY)

Orion Portfolio Solutions LLC grew its position in Eli Lilly and Company (NYSE:LLY) by 13.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 43,569 shares of the company’s stock after purchasing an additional 5,327 shares during the period. Orion Portfolio Solutions LLC’s holdings in Eli Lilly and Company were worth $33,635,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in LLY. Principal Financial Group Inc. lifted its holdings in Eli Lilly and Company by 5.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock worth $1,070,698,000 after buying an additional 60,306 shares in the last quarter. Penserra Capital Management LLC boosted its holdings in Eli Lilly and Company by 45.2% in the third quarter. Penserra Capital Management LLC now owns 870 shares of the company’s stock valued at $770,000 after acquiring an additional 271 shares during the last quarter. Loomis Sayles & Co. L P increased its position in Eli Lilly and Company by 24.7% in the third quarter. Loomis Sayles & Co. L P now owns 1,869 shares of the company’s stock worth $1,656,000 after purchasing an additional 370 shares during the period. Quantbot Technologies LP raised its holdings in Eli Lilly and Company by 115.3% during the 3rd quarter. Quantbot Technologies LP now owns 3,757 shares of the company’s stock worth $3,328,000 after purchasing an additional 2,012 shares during the last quarter. Finally, Blueshift Asset Management LLC acquired a new position in Eli Lilly and Company during the 3rd quarter valued at about $881,000. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $822.14 on Friday. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a fifty-two week low of $711.40 and a fifty-two week high of $972.53. The company has a market cap of $779.52 billion, a price-to-earnings ratio of 70.21, a PEG ratio of 1.40 and a beta of 0.34. The stock has a fifty day moving average price of $842.43 and a 200-day moving average price of $837.43.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company announced that its Board of Directors has authorized a share repurchase program on Monday, December 9th that permits the company to buyback $15.00 billion in outstanding shares. This buyback authorization permits the company to reacquire up to 2% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s leadership believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on LLY. Wells Fargo & Company increased their price target on Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Citigroup decreased their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Morgan Stanley set a $1,146.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, March 6th. Finally, Truist Financial upped their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Three research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,009.72.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.